-
EP3747909
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3747909
| EP3747909 - ANTICANCER AGENT [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 03.05.2024 Database last updated on 06.07.2024 | |
| Former | Request for examination was made Status updated on 06.11.2020 | ||
| Former | The international publication has been made Status updated on 10.08.2019 | Most recent event Tooltip | 07.05.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Osaka University 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | [2022/16] |
| Former [2020/50] | For all designated states Osaka University 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | ||
| For all designated states Tokyo Institute of Technology 2-12-1, Ookayama Meguro-ku Tokyo 152-8550 / JP | Inventor(s) | 01 /
MORI, Masaki c/o OSAKA UNIVERSITY, 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 02 /
ISHII, Hideshi c/o OSAKA UNIVERSITY, 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 03 /
KONNO, Masamitsu c/o OSAKA UNIVERSITY, 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 04 /
EGUCHI, Hidetoshi c/o OSAKA UNIVERSITY, 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 05 /
HARAGUCHI, Naotsugu c/o OSAKA UNIVERSITY, 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 06 /
TOSHIYAMA, Reishi c/o OSAKA UNIVERSITY, 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 07 /
NISHIYAMA, Nobuhiro c/o TOKYO INSTITUTE OF TECHNOLOGY, 2-12-1, Ookayama, Meguro-ku Tokyo 152-8550 / JP | 08 /
TAKEMOTO, Hiroyasu c/o TOKYO INSTITUTE OF TECHNOLOGY, 2-12-1, Ookayama, Meguro-ku Tokyo 152-8550 / JP | [2020/50] | Representative(s) | Müller-Boré & Partner Patentanwälte PartG mbB Friedenheimer Brücke 21 80639 München / DE | [2020/50] | Application number, filing date | 19748189.8 | 30.01.2019 | [2020/50] | WO2019JP03150 | Priority number, date | JP20180013678 | 30.01.2018 Original published format: JP 2018013678 | [2020/50] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019151320 | Date: | 08.08.2019 | Language: | JA | [2019/32] | Type: | A1 Application with search report | No.: | EP3747909 | Date: | 09.12.2020 | Language: | EN | [2020/50] | Search report(s) | International search report - published on: | JP | 08.08.2019 | (Supplementary) European search report - dispatched on: | EP | 12.08.2021 | Classification | IPC: | C07K14/00, C07C255/00, A61K31/165, A61K31/198, A61K31/785, A61K47/42, A61K47/60, A61K47/64, A61P35/00 | [2021/37] | CPC: |
C07K14/001 (EP);
A61K47/64 (US);
A61K31/513 (EP,US);
A61K31/704 (EP,US);
A61K33/243 (EP,US);
A61K45/06 (EP);
A61K47/42 (EP);
A61K47/60 (EP);
A61K47/645 (EP);
A61K9/0019 (EP);
A61P35/00 (EP,US);
C07K5/0202 (EP);
| C-Set: |
A61K31/513, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP);
A61K33/243, A61K2300/00 (EP)
|
| Former IPC [2020/50] | C07K19/00, A61K31/198, A61K31/785, A61K45/00, A61K47/34, A61K47/42, A61K47/60, A61K47/64, A61P35/00, A61P43/00, C07K5/06, C07K14/81, C12N9/99, C12N9/64 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/50] | Title | German: | ANTIKREBSMITTEL | [2020/50] | English: | ANTICANCER AGENT | [2020/50] | French: | AGENT ANTICANCÉREUX | [2020/50] | Entry into regional phase | 10.08.2020 | Translation filed | 13.08.2020 | National basic fee paid | 13.08.2020 | Search fee paid | 13.08.2020 | Designation fee(s) paid | 13.08.2020 | Examination fee paid | Examination procedure | 05.08.2019 | Request for preliminary examination filed International Preliminary Examining Authority: JP | 13.08.2020 | Examination requested [2020/50] | 01.02.2022 | Amendment by applicant (claims and/or description) | 06.05.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 13.08.2020 | Renewal fee patent year 03 | 18.01.2022 | Renewal fee patent year 04 | 20.01.2023 | Renewal fee patent year 05 | 11.01.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2010005740 (BIND BIOSCIENCES INC [US], et al) [A] 1-15 * page 5 ** page 31, line 25 *; | [X]EP2258397 (NIPPON KAYAKU KK [JP]) [X] 1-15 * general formula (II); test example 2; paragraph [0021]; example 5; claims 1-24 *; | [X]WO2013024048 (ASCENDIS PHARMA AS [DK], et al) [X] 1-15 * pages 26 to 29; pages 33 to 36; page 92, line 4; examples 2,3; claims 1-14 *; | [X]WO2017170845 (NANOCARRIER CO LTD [JP]) [X] 1-15 * paragraph [0014]; claims 1-20 * | International search | [Y]JP2002515418 (EXPRESSION GENETICS, INC.) [Y] 1-15 * , abstract, background & US 6177274 Bl, abstract, background of the invention & WO 1999/059546 A1 & EP 1083882 A *; | [Y]JP2017105800 (UNIV TOKYO, et al) [Y] 1-15 * , abstract, examples & US 2018/0153920 A, abstract, examples & WO 2013/162041 A & EP 2842546 A1 *; | [Y] - YAMASHITA, MASAFUMI et al., "A CD 13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma", International journal of oncology, (20160000), vol. 49, pages 89 - 98, XP055628479 [Y] 1-15 * , abstract, introduction, results * DOI: http://dx.doi.org/10.3892/ijo.2016.3496 | [Y] - ZHOU, ZHUXIAN et al., "A multifunctional PEG-PLL drug conjugate forming redox-responsive nanoparticles for intracellular drug delivery", Journal of materials chemistry B, (20150000), vol. 3, pages 7594 - 7603, XP055628483 [Y] 1-15 * , abstract, materials * DOI: http://dx.doi.org/10.1039/C5TB01027F | [PX] - TOSHIYAMA, REISHI et al., "Poly(ethylene glycol)- poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells", Oncogene, (20180800), vol. 38, no. 2, pages 244 - 260, XP036668959 [PX] 1-15 * , materials and methods, results, fig. 2 * DOI: http://dx.doi.org/10.1038/s41388-018-0406-x | by applicant | - YAMASHITA MWADA HEGUCHI HOGAWA HYAMADA DNODA T et al., "A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma", Int J Oncol, (20160000), vol. 49, doi:10.3892/ijo.2016.3496, pages 89 - 98, XP055628479 DOI: http://dx.doi.org/10.3892/ijo.2016.3496 |